Mrinal Gounder
姆里纳尔·高德
MD
Associate Attending Physician, Sarcoma Medical Oncology肉瘤内科肿瘤学副主任医师
👥Biography 个人简介
Mrinal Gounder, MD is a sarcoma medical oncologist at MSK renowned for leading the pivotal RINGSIDE phase III trial of nirogacestat in desmoid tumors, the first positive randomized trial in this disease. He has defined molecular targets and therapeutic strategies across multiple STS subtypes and leads global clinical development of novel agents.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Desmoid Tumor Therapy
Led the RINGSIDE trial demonstrating nirogacestat (gamma secretase inhibitor) significantly improved progression-free survival in desmoid tumors, establishing the first approved targeted therapy for this disease in 2023.
STS Targeted Therapy
Developed clinical programs targeting MDM2, CDK4, and WNT/NOTCH pathways across liposarcoma, desmoid tumor, and other STS subtypes, advancing precision oncology in rare sarcomas.
Representative Works 代表性著作
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors (RINGSIDE Trial)
New England Journal of Medicine (2023)
Phase III trial showing nirogacestat improved PFS vs placebo in desmoid tumors, leading to FDA approval — a landmark first for this rare disease.
Sorafenib for Advanced and Refractory Desmoid Tumors: A Phase II Randomized Controlled Trial
JAMA Oncology (2018)
Demonstrated sorafenib's activity in desmoid tumors in a randomized setting, providing an evidence-based systemic option prior to nirogacestat approval.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 姆里纳尔·高德 的研究动态
Follow Mrinal Gounder's research updates
留下邮箱，当我们发布与 Mrinal Gounder（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment